ArticleBMC cancer2020
Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators.
Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Informing prostate cancer screening policy makers in the European Union: lessons from cancer screening governance and policymaking.European journal of public health · 2025Pooled it
- Developing and validating key performance indicators for breast, cervical, and colorectal cancer screening programs: a literature review and Delphi survey.Frontiers in public health · 2025Pooled it
- Test performance metrics for breast, cervical, colon, and lung cancer screening: a systematic review.Journal of the National Cancer Institute · 2023Pooled it
- The GIN-McMaster guideline tool extension for the integration of quality improvement and quality assurance in guidelines: a description of the methods for its development.Journal of clinical epidemiology · 2023Pooled it
- Optimising screening intervals and BI-RADS management pathways in ultrasound-based breast cancer screening: real-world evidence from Shenzhen (2018-2023).Breast cancer research and treatment · 2026Article
- Indicators to identify cancer screening providers with suboptimal case detection: A scoping review.International journal of cancer · 2026Article
- Age-related prognoses in a Luxembourgish breast cancer cohort.Frontiers in oncology · 2026Article
- Evaluation of breast cancer screening programmes: Candidate performance indicators and their association with breast cancer mortality.Breast (Edinburgh, Scotland) · 2025Article
- Low participation in cancer screening in India: a scoping review of breast and cervical cancer programs.BMC cancer · 2025Article
- Thirty years of population-based breast cancer screening in Iceland: a comparison of quality indicators and tumour characteristics between women aged 40-49 and 50-69 years.Acta oncologica (Stockholm, Sweden) · 2025Article
- Delays in follow-up among women with abnormal results: a retrospective study based on population-based breast cancer screening programme in China.BMC public health · 2025Article
- Outcomes of the Saudi breast cancer early detection program: a nine-year analysis (2012-2020).Breast cancer research and treatment · 2025Article
- Monitoring of prostate cancer screening in the European Union: development of key performance indicators through the PRAISE-U project.EClinicalMedicine · 2025Article
- From genetic risk to early detection - clinical outcomes of a person-centered screening program for women with a high genetic risk of breast cancer.Frontiers in oncology · 2025Article
- Bridging gaps in breast cancer care: a Breast Cancer Care Quality Index to improve outcomes worldwide.Ecancermedicalscience · 2025Article
- Comparisons of assessment pathways after abnormal mammography screening in Denmark, Norway, and Spain.Breast cancer research and treatment · 2024Article
- Interval cancer audit and disclosure in breast screening programmes: An international survey.Journal of medical screening · 2023Article
- Factors influencing participation in breast cancer screening in an urban setting. A study of organized and individual opportunistic screening among potentially active and retired women in the city of Nice.Preventive medicine reports · 2023Article
- A nomogram for predicting breast cancer based on hematologic and ultrasound parameters.American journal of translational research · 2023Article
- Evaluation of participation and performance indicators in a breast cancer screening program in Saudi Arabia.Saudi medical journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 17 institutions in 11 countries.
Funding
Abstract
backgroundIn the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection.
methodsThe indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries.
resultsA total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate.
conclusionThis systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.